Page 68 - Haematologica - Vol. 105 n. 6 - June 2020

L.A. Richards et al.
of mouse telomerase in highly proliferative
organs. Nature. 1998;392(6676):569-574.
9. Hiyama K, Hirai Y, Kyoizumi S, et al. Activation of telomerase in human lympho- cytes and hematopoietic progenitor cells. J
Immunol. 1995;155(8):3711-3715.
10. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci U S
A. 1995;92(20):9082-9086.
11. Engelhardt M, Kumar R, Albanell J,
Pettengell R, Han W, Moore MA. Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells. Blood. 1997;90(1):182-193.
12. Chiu CP, Dragowska W, Kim NW, Vaziri H, Yui J, Thomas TE, et al. Differential expres- sion of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells. 1996;14(2):239-248.
13. Yamada O, Motoji T, Mizoguchi H. Up-reg- ulation of telomerase activity in human lym- phocytes. Biochim Biophys Acta. 1996;1314 (3):260-266.
14. Schuller CE, Jankowski K, Mackenzie KL. Telomere length of cord blood-derived CD34(+) progenitors predicts erythroid pro- liferative potential. Leukemia. 2007;21(5): 983-991.
15. Raval A, Behbehani GK, Nguyen le XT, et al. Reversibility of defective hematopoiesis caused by telomere shortening in telomerase knockout Mice. PLoS One. 2015;10(7): e0131722.
16. Balakumaran A, Mishra PJ, Pawelczyk E, et al. Bone marrow skeletal stem/progenitor cell defects in dyskeratosis congenita and telomere biology disorders. Blood. 2015; 125(5):793-802.
17. Barbaro PM, Ziegler DS, Reddel RR. The wide-ranging clinical implications of the short telomere syndromes. Intern Med J. 2016;46(4):393-403.
18. Kirwan M, Vulliamy T, Beswick R, Walne AJ, Casimir C, Dokal I. Circulating haematopoi- etic progenitors are differentially reduced amongst subtypes of dyskeratosis congenita. Br J Haematol. 2008;140(6):719-722.
19. Wu KJ, Grandori C, Amacker M, et al. Direct activation of TERT transcription by c-MYC. Nat Genet. 1999;21(2):220-224.
20. Xu D, Gruber A, Bjorkholm M, Peterson C, Pisa P. Suppression of telomerase reverse transcriptase (hTERT) expression in differen- tiated HL-60 cells: regulatory mechanisms. Br J Cancer. 1999;80(8):1156-1161.
21. Uchida N, Otsuka T, Shigematsu H, et al. Differential gene expression of human telomerase-associated protein hTERT and TEP1 in human hematopoietic cells. Leuk Res. 1999;23(12):1127-1132.
22. Maritz MF, Richards LA, Mackenzie KL. Assessment and quantification of telomerase enzyme activity. Methods Mol Biol. 2013;965:215-231.
23. Taylor LM, James A, Schuller CE, Brce J, Lock RB, Mackenzie KL. Inactivation of p16INK4a, with retention of pRB and p53/p21cip1 function, in human MRC5 fibroblasts that overcome a telomere-inde- pendent crisis during immortalization. J Biol Chem. 2004;279(42):43634-43645.
24. Beck D, Thoms JA, Perera D, et al. Genome- wide analysis of transcriptional regulators in human HSPCs reveals a densely intercon- nected network of coding and noncoding genes. Blood. 2013;122(14):e12-22.
25. Wu C, Orozco C, Boyer J, et al. BioGPS: an
extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009;10(11):R130.
26. Alawi F, Lee MN. DKC1 is a direct and con- served transcriptional target of c-MYC. Biochem Biophys Res Commun. 2007;362 (4):893-898.
27. O'Brien R, Tran SL, Maritz MF, et al. MYC- driven neuroblastomas are addicted to a telomerase-independent function of dyskerin. Cancer Res. 2016;76(12):3604- 3617.
28. Bondurant MC, Yamashita T, Muta K, Krantz SB, Koury MJ. C-myc expression affects proliferation but not terminal differ- entiation or survival of explanted erythroid progenitor cells. J Cell Physiol. 1996;168(2): 255-263.
29. Shilatifard A. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr Opin Cell Biol. 2008;20(3):341-348.
30. Xu J, Shao Z, Glass K, Bauer DE, et al. Combinatorial assembly of developmental stage-specific enhancers controls gene expression programs during human erythro- poiesis. Dev Cell. 2012;23(4):796-811.
31. Hu G, Schones DE, Cui K, et al. Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res. 2011;21(10):1650- 1658.
32. Zheng R, Wan C, Mei S, et al. Cistrome Data Browser: expanded datasets and new tools for gene regulatory analysis. Nucleic Acids Res. 2019;47(D1):D729-D35.
33. Koyanagi Y, Kobayashi D, Yajima T, et al. Telomerase activity is down regulated via decreases in hTERT mRNA but not TEP1 mRNA or hTERC during the differentiation of leukemic cells. Anticancer Res. 2000;20(2A):773-778.
34. Chang JT, Chen YL, Yang HT, Chen CY, Cheng AJ. Differential regulation of telom- erase activity by six telomerase subunits. Eur J Biochem. 2002;269(14):3442-3450.
35. Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ, Weng NP. Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lympho- cytes. Proc Natl Acad Sci U S A. 1999;96(9):5147-5152.
36. Sharma HW, Sokoloski JA, Perez JR, et al. Differentiation of immortal cells inhibits telomerase activity. Proc Natl Acad Sci U S A. 1995;92(26):12343-12346.
37. Xu D, Popov N, Hou M, et al. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telom- erase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A. 2001;98(7):3826-3831.
38. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999;402 (6761):551-555.
39. Kirwan M, Beswick R, Vulliamy T, et al. Exogenous TERC alone can enhance prolifer- ative potential, telomerase activity and telomere length in lymphocytes from dyskeratosis congenita patients. Br J Haematol. 2009;144(5):771-781.
40. Napier CE, Veas LA, Kan CY, et al. Mild hyperoxia limits hTR levels, telomerase activity, and telomere length maintenance in hTERT-transduced bone marrow endothelial cells. Biochim Biophys Acta. 2010;1803(10): 1142-1153.
41. Cao Y, Huschtscha LI, Nouwens AS, et al. Amplification of telomerase reverse tran- scriptase gene in human mammary epithelial cells with limiting telomerase RNA expres- sion levels. Cancer Res. 2008;68(9):3115- 3123.
42. Kim NK, Theimer CA, Mitchell JR, Collins K, Feigon J. Effect of pseudouridylation on the structure and activity of the catalytically essential P6.1 hairpin in human telomerase RNA. Nucleic Acids Res. 2010;38(19):6746- 6756.
43. Meier UT. The many facets of H/ACA ribonucleoproteins. Chromosoma. 2005;114 (1):1-14.
44. Jack K, Bellodi C, Landry DM, et al. rRNA pseudouridylation defects affect ribosomal ligand binding and translational fidelity from yeast to human cells. Mol Cell. 2011;44(4):660-666.
45. Heiss NS, Knight SW, Vulliamy TJ, et al. X- linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 1998;19(1):32-38.
46. Watkins NJ, Gottschalk A, Neubauer G, et al. Cbf5p, a potential pseudouridine synthase, and Nhp2p, a putative RNA-binding protein, are present together with Gar1p in all H BOX/ACA-motif snoRNPs and constitute a common bipartite structure. RNA. 1998;4(12):1549-1568.
47. Ender C, Krek A, Friedlander MR, et al. A human snoRNA with microRNA-like func- tions. Mol Cell. 2008;32(4):519-528.
48. Scott MS, Ono M. From snoRNA to miRNA: dual function regulatory non-coding RNAs. Biochimie. 2011;93(11):1987-1992.
49. Yoon A, Peng G, Brandenburger Y, et al. Impaired control of IRES-mediated transla- tion in X-linked dyskeratosis congenita. Science. 2006;312(5775):902-906.
50. Mochizuki Y, He J, Kulkarni S, Bessler M, Mason PJ. Mouse dyskerin mutations affect accumulation of telomerase RNA and small nucleolar RNA, telomerase activity, and ribo- somal RNA processing. Proc Natl Acad Sci U S A. 2004;101(29):10756-10761.
51. Ruggero D, Grisendi S, Piazza F, et al. Dyskeratosis congenita and cancer in mice deficient in ribosomal RNA modification. Science. 2003;299(5604):259-262.
52. Ge J, Rudnick DA, He J, et al. Dyskerin abla- tion in mouse liver inhibits rRNA processing and cell division. Mol Cell Biol. 2010;30(2):413-422.
53. Pereboom TC, van Weele LJ, Bondt A, MacInnes AW. A zebrafish model of dysker- atosis congenita reveals hematopoietic stem cell formation failure resulting from riboso- mal protein-mediated p53 stabilization. Blood. 2011;118(20):5458-5465.
54. Zivot A, Lipton JM, Narla A, Blanc L. Erythropoiesis: insights into pathophysiolo- gy and treatments in 2017. Mol Med. 2018;24(1):11.
55. Raiser DM, Narla A, Ebert BL. The emerging importance of ribosomal dysfunction in the pathogenesis of hematologic disorders. Leuk Lymphoma. 2014;55(3):491-500.
56. Parrella S, Aspesi A, Quarello P, et al. Loss of GATA-1 full length as a cause of Diamond- Blackfan anemia phenotype. Pediatr Blood Cancer. 2014;61(7):1319-1321.
57. Liu Y, Snow BE, Hande MP, et al. The telom- erase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol. 2000;10(22):1459-1462.
1526
haematologica | 2020; 105(6)